X4 Pharmaceuticals, Inc. Common Stock (XFOR) — Analysis Summary
X4 Pharmaceuticals, Inc. Common Stock (XFOR) has a market cap of $406.52M with year-over-year revenue growth of +1273.2%. Net margin stands at -225.6%. The stock trades at a P/E ratio of -4.1.
Key Takeaways
- Revenue changed +1273.2% year-over-year
- Net margin of -225.6%
- P/E ratio of -4.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, XFOR posted revenue growth of +1273.2% and trades at a P/E of -4.1.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.